Company overview
NEOsphere Biotechnologies provides a proteomics-based platform for targeted protein degradation (TPD) drug discovery, enabling high-throughput characterization and optimization of degrader compounds. Their technology offers proteome-wide screening, precise quantification, and rapid turnaround to identify novel targets and advance programs. Based in Munich, Germany, they partner with pharma companies like Kymera Therapeutics to accelerate TPD development.
Neosphere Biotechnologies is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents partner serving United States & Americas. Core focus areas include targeted protein degradation, proteomics platform, degrader drug discovery, mass spectrometry, tpd screening.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Neosphere Biotechnologies include Mass Spectrometry — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://neospherebiotechnologies.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- targeted protein degradation, proteomics platform, degrader drug discovery, mass spectrometry, tpd screening
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What capabilities does NEOsphere offer for targeted protein degradation?
- NEOsphere provides a target- and E3-agnostic proteomics platform for high-throughput screening of degrader compounds, target identification, compound optimization, and proteome-wide analysis with neoVERSE data tools.
- What are NEOsphere's regulatory and quality standards?
- As a biotech founded in 2022 specializing in mass spectrometry proteomics, NEOsphere demonstrates scientific excellence through publications in top-tier journals, supporting rigorous drug discovery standards.
- Where does NEOsphere operate and serve clients?
- NEOsphere Biotechnologies is based in Munich, Germany, and collaborates globally with partners like Kymera Therapeutics to advance TPD programs in pharma and biotech.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
